Plain-language summary

This Phase 1, Phase 2 trial is evaluating Linperlisib, Camrelizumab, and other medications as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join (key eligibility)

• Age 18 Years to 75 Years years
• Newly diagnosed, not yet treated
• Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Linperlisib (DRUG): Linperlisib: Phase Ib, oral, 80 mg/d, QD; Phase II, oral, RP2D, QD. | Camrelizumab (DRUG): Camrelizumab for Injection: 200 mg/d, intravenous drip for 30 min (not less than 20 min and not more than 60 min), administered on day 1 of each cycle, observed for 2 hours after infusion. Every 3 weeks is a dosing cycle. Cycle 2 and subsequent cycles of dosing may be administered up to 5 days before or after the day of the scheduled dosing; more than 3 days after the date of the scheduled dosing will be considered a delayed dosing. | Pegaspargase (DRUG): Pegaspargase: 2500 IU/m2, intramuscular injection, divided into three places, administered on the first day of each cycle, observed 2 hours after injection for the occurrence of anaphylactic reaction, if there is no anaphylactic reaction before giving other test drugs. Every 3 weeks as a dosing cycle. Camrelizumab for Injection should not be applied on the same day as Dexamethasonee. | Dexamethasone (DRUG): Dexamethasone, 20 mg/d, days 1-4. Camrelizumab for Injection should not be applied on the same day as Dexamethasonee.

Drugs / treatments

Linperlisib, Camrelizumab, Pegaspargase, Dexamethasone

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details